Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.

Donken R, Dobson SRM, Marty KD, Cook D, Sauvageau C, Gilca V, Dionne M, McNeil S, Krajden M, Money D, Kellner J, Scheifele DW, Kollmann T, Bettinger JA, Liu S, Singer J, Naus M, Sadarangani M, Ogilvie GS.

Clin Infect Dis. 2019 Sep 6. pii: ciz887. doi: 10.1093/cid/ciz887. [Epub ahead of print]

PMID:
31617568
2.

Will Infant Hepatitis B Immunization Protect Adults?

Scheifele DW.

Pediatr Infect Dis J. 2019 Jun;38(6S Suppl 1):S64-S66. doi: 10.1097/INF.0000000000002326.

PMID:
31205248
3.

Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison.

Kumar A, McElhaney JE, Walrond L, Cyr TD, Merani S, Kollmann TR, Halperin SA, Scheifele DW.

Hum Vaccin Immunother. 2017 Sep 2;13(9):2048-2057. doi: 10.1080/21645515.2017.1337615. Epub 2017 Jun 21.

4.

Maternal immunisation: collaborating with mother nature.

Marchant A, Sadarangani M, Garand M, Dauby N, Verhasselt V, Pereira L, Bjornson G, Jones CE, Halperin SA, Edwards KM, Heath P, Openshaw PJ, Scheifele DW, Kollmann TR.

Lancet Infect Dis. 2017 Jul;17(7):e197-e208. doi: 10.1016/S1473-3099(17)30229-3. Epub 2017 Apr 19. Review.

5.

Pertussis and influenza immunisation during pregnancy: a landscape review.

Abu Raya B, Edwards KM, Scheifele DW, Halperin SA.

Lancet Infect Dis. 2017 Jul;17(7):e209-e222. doi: 10.1016/S1473-3099(17)30190-1. Epub 2017 Apr 19. Review.

PMID:
28433704
6.

Will Infant Hepatitis B Vaccination Protect Into Adulthood?: Extended Canadian Experience After a 2-, 4- and 6-month Immunization Schedule.

Pinto M, Dawar M, Krajden M, Naus M, Scheifele DW.

Pediatr Infect Dis J. 2017 Jun;36(6):609-615. doi: 10.1097/INF.0000000000001543.

PMID:
28134742
7.

Do Dose Numbers Matter?: Evaluation of Differing Infant and Toddler Meningococcal C Conjugate Vaccine Programs in Canadian Children.

Bettinger JA, Vanderkooi OG, Scheifele DW, Halperin SA, Kellner JD, Schryvers A, De Serres G, Alcantara J.

Pediatr Infect Dis J. 2016 Nov;35(11):1242-1246.

PMID:
27753770
8.

Hospitalization for Influenza A Versus B.

Tran D, Vaudry W, Moore D, Bettinger JA, Halperin SA, Scheifele DW, Jadvji T, Lee L, Mersereau T; members of the Canadian Immunization Monitoring Program Active.

Pediatrics. 2016 Sep;138(3). pii: e20154643. doi: 10.1542/peds.2015-4643. Epub 2016 Aug 17.

9.

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.

Scheifele DW, Ferguson M, Predy G, Dawar M, Assudani D, Kuriyakose S, Van Der Meeren O, Han HH.

Vaccine. 2015 Apr 15;33(16):1897-900. doi: 10.1016/j.vaccine.2015.02.015. Epub 2015 Feb 18.

10.

Canadian vaccine research networks: Vaccine safety resources for Canada.

McCarthy J, Halperin SA, Bettinger JA, Langley JM, Crowcroft NS, Deeks S, Kwong JC, De Serres G, Top K, McNeil S, Scheifele DW; Canadian Immunization Research Network (CIRN) Investigators.

Can Commun Dis Rep. 2015 Feb 20;41(Suppl 1):18-23. eCollection 2015 Feb 20.

11.

Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study.

Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA; investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT).

Clin Infect Dis. 2015 Apr 15;60(8):e27-35. doi: 10.1093/cid/civ028. Epub 2015 Jan 20.

PMID:
25605282
12.

The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases.

Bettinger JA, Halperin SA, Vaudry W, Law BJ, Scheifele DW; Canadian IMPACT members.

Can Commun Dis Rep. 2014 Dec 4;40(Suppl 3):41-44. eCollection 2014 Dec 4.

13.

The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012.

Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA; investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT).

Clin Infect Dis. 2014 Nov 1;59(9):1208-15. doi: 10.1093/cid/ciu597. Epub 2014 Jul 28.

PMID:
25069868
14.

Burden of seasonal influenza in children with neurodevelopmental conditions.

Burton C, Vaudry W, Moore D, Bettinger JA, Tran D, Halperin SA, Scheifele DW; IMPACT investigators.

Pediatr Infect Dis J. 2014 Jul;33(7):710-4. doi: 10.1097/INF.0000000000000272.

PMID:
24918745
15.

Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation.

Schneeberg A, Bettinger JA, McNeil S, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Scheifele DW, Halperin SA.

BMC Public Health. 2014 May 12;14:442. doi: 10.1186/1471-2458-14-442.

16.

Childhood immunization rates in Canada are too low: UNICEF.

Scheifele DW, Halperin SA, Bettinger JA.

Paediatr Child Health. 2014 May;19(5):237-8. No abstract available.

17.

How best to describe the risk of meningococcal B infection?

Sadarangani M, Bettinger JA, Scheifele DW.

Paediatr Child Health. 2013 Dec;18(10):543-4. No abstract available.

18.

Approved but non-funded vaccines: accessing individual protection.

Scheifele DW, Ward BJ, Halperin SA, McNeil SA, Crowcroft NS, Bjornson G.

Vaccine. 2014 Feb 7;32(7):766-70. doi: 10.1016/j.vaccine.2013.12.027. Epub 2013 Dec 25. Review.

19.

Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada.

Top KA, Constantinescu CM, Laflèche J, Bettinger JA, Scheifele DW, Vaudry W, Halperin SA, Law BJ.

Vaccine. 2013 Nov 19;31(48):5700-5. doi: 10.1016/j.vaccine.2013.09.048. Epub 2013 Oct 5.

PMID:
24099871
20.

Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.

Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA; PHAC /CIHR Influenza Research Network.

Hum Vaccin Immunother. 2013 Nov;9(11):2460-73. Epub 2013 Jul 9.

21.

Cost effectiveness of infant vaccination for rotavirus in Canada.

Coyle D, Coyle K, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW, Le Saux N.

Can J Infect Dis Med Microbiol. 2012 Summer;23(2):71-7.

22.

Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a public health agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study.

Al-Dabbagh M, Lapphra K, Scheifele DW, Halperin SA, Langley JM, Cho P, Kollmann TR, Li Y, De Serres G, Fortuno ES 3rd, Bettinger JA.

Clin Vaccine Immunol. 2013 Aug;20(8):1108-14. doi: 10.1128/CVI.00659-12. Epub 2013 May 22.

23.

Controlling serogroup B invasive meningococcal disease: the Canadian perspective.

Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW.

Expert Rev Vaccines. 2013 May;12(5):505-17. doi: 10.1586/erv.13.30. Review.

PMID:
23659299
24.

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E.

JAMA. 2013 May 1;309(17):1793-802. doi: 10.1001/jama.2013.1625.

PMID:
23632723
25.

Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).

Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT).

Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12.

26.

Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial.

Scheifele DW, Dionne M, Ward BJ, Cooper C, Vanderkooi OG, Li Y, Halperin SA; PHAC/CIHR Influenza Research Network.

Hum Vaccin Immunother. 2013 Jan;9(1):136-43.

27.

Response to the changing epidemiology of meningococcal disease in North America 1945-2010.

Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Le Saux N.

Hum Vaccin Immunother. 2013 Jun;9(6):1323-4. doi: 10.4161/hv.24009. Epub 2013 Mar 1. No abstract available.

28.

Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ; Public Health Agency of Canada/Canadian Institute of Health Research, Influenza Research Network (PCIRN) Rapid Trial Study 3 (RT-03) Investigators.

Clin Vaccine Immunol. 2013 Apr;20(4):459-67. doi: 10.1128/CVI.00619-12. Epub 2013 Jan 23.

29.

Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009.

Tran D, Vaudry W, Moore DL, Bettinger JA, Halperin SA, Scheifele DW, Aziz S; IMPACT investigators.

Pediatrics. 2012 Sep;130(3):397-406. Epub 2012 Aug 29.

PMID:
22931901
30.

The disease burden of invasive meningococcal serogroup B disease in Canada.

Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Members of Canadian Immunization Monitoring Program, Active (IMPACT).

Pediatr Infect Dis J. 2013 Jan;32(1):e20-5. doi: 10.1097/INF.0b013e3182706b89.

PMID:
22926207
31.

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).

Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y.

J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7.

PMID:
22872731
32.

Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.

Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, Li Y; PHAC/CIHR Influenza Research Network (PCIRN).

Vaccine. 2012 Jul 6;30(32):4728-32. doi: 10.1016/j.vaccine.2012.05.029. Epub 2012 May 28.

PMID:
22652402
33.

Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.

Bettinger JA, Scheifele DW, Halperin SA, Kellner JD, Vanderkooi OG, Schryvers A, De Serres G, Alcantara J.

Vaccine. 2012 Jun 8;30(27):4023-7. doi: 10.1016/j.vaccine.2012.04.034. Epub 2012 Apr 23.

PMID:
22537988
34.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860
35.

Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillance.

Bettinger JA, Wills K, Le Saux N, Scheifele DW, Halperin SA, Vaudry W.

Can J Infect Dis Med Microbiol. 2011 Spring;22(1):15-8.

36.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD; Canadian PCV13 Study Group.

Pediatr Infect Dis J. 2012 Jan;31(1):72-7. doi: 10.1097/INF.0b013e318233049d.

PMID:
21960186
37.

Strategies for successful rapid trials of influenza vaccine.

Scheifele DW, Marty K, LaJeunesse C, Fan SY, Bjornson G, Langley JM, Halperin SA.

Clin Trials. 2011 Dec;8(6):699-704. doi: 10.1177/1740774511419868. Epub 2011 Sep 7.

PMID:
21900340
38.

Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months.

Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabaiduc S, Petric M.

Pediatrics. 2011 Aug;128(2):e276-89. doi: 10.1542/peds.2010-2777. Epub 2011 Jul 18.

PMID:
21768314
39.

Optimizing Canadian public immunization programs: a prescription for action.

Scheifele DW, Naus M, Crowcroft NS, Dobson S, Halperin SA, Bjornson G.

Can J Public Health. 2011 May-Jun;102(3):193-5.

PMID:
21714317
40.

Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children.

Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA; Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators.

Pediatr Infect Dis J. 2011 May;30(5):402-7. doi: 10.1097/INF.0b013e3182068f33.

PMID:
21178654
41.

Severe genital ulceration in an acute epstein-barr virus infection.

Al-Rawahi GN, Dobson SR, Scheifele DW, Rassekh SR, Murphy JJ.

Pediatr Infect Dis J. 2011 Feb;30(2):176-8. doi: 10.1097/INF.0b013e3181f41b2e.

PMID:
20736877
42.

Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination.

Lapphra K, Huh L, Scheifele DW.

Pediatr Infect Dis J. 2011 Jan;30(1):84-6. doi: 10.1097/INF.0b013e3181f11126.

PMID:
20686434
43.

A nationwide survey of past hepatitis A infections among Canadian adults.

Scheifele DW, De Serres G, Gilca V, Duval B, Milner R, Ho M, Ochnio JJ.

Vaccine. 2010 Jul 19;28(32):5174-8. doi: 10.1016/j.vaccine.2010.05.076. Epub 2010 Jun 15.

PMID:
20558251
44.

Substantial morbidity for hospitalized children with community-acquired rotavirus infections: 2005-2007 IMPACT surveillance in Canadian hospitals.

Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW; Canadian Immunization Monitoring Program, Active (IMPACT).

Pediatr Infect Dis J. 2010 Sep;29(9):879-82. doi: 10.1097/INF.0b013e3181e20c94.

PMID:
20467353
45.

Pandemic influenza in Canadian children: a summary of hospitalized pediatric cases.

Bettinger JA, Sauvé LJ, Scheifele DW, Moore D, Vaudry W, Tran D, Halperin SA, Pelletier L.

Vaccine. 2010 Apr 19;28(18):3180-4. doi: 10.1016/j.vaccine.2010.02.044. Epub 2010 Feb 26.

PMID:
20189488
46.

The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007.

Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, Law B, Tyrrell G; Canadian Immunization Monitoring Program, Active (IMPACT).

Vaccine. 2010 Feb 25;28(9):2130-6. doi: 10.1016/j.vaccine.2009.12.026. Epub 2009 Dec 29.

PMID:
20044050
47.

Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.

Scheifele DW, Ochnio JJ, Halperin SA.

Pediatr Infect Dis J. 2009 Nov;28(11):985-9. doi: 10.1097/INF.0b013e3181a9cc2a.

PMID:
19755930
48.

Pediatric combined formulation DTaP-IPV/Hib vaccine.

White C, Halperin SA, Scheifele DW.

Expert Rev Vaccines. 2009 Jul;8(7):831-40. doi: 10.1586/erv.09.59. Review.

PMID:
19538110
49.

Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study.

Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW.

Clin Infect Dis. 2009 Jul 15;49(2):205-12. doi: 10.1086/599827.

PMID:
19508165

Supplemental Content

Loading ...
Support Center